This site is intended for healthcare professionals
Following a review, NICE have overturned their previous negative decision for abatacept (Orencia) following the introduction of a patient access scheme.
Previously, abatacept was only approved for use in rheumatoid arthritis after the failure of a TNF inhibitor. Now it may also be used in adults whose disease has responded inadequately to 2 conventional disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, provided the manufacturer supplies abatacept with the discount agreed in the patient access scheme.
NICE guidance on abatacept in rheumatoid arthritis after failure of conventional DMARDS
Medac has launched Metoject PEN (methotrexate) a single-use...
BMS has launched a prefilled syringe presentation of...
NICE has overturned its original decision to reject...
The most up-to-date drug information at your fingertips.
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
GPs should consider online vestibular rehabilitation...
Added: Evorel and galantamine.
Use our constantly...
Thiazide diuretics are more effective than ACE inhibitors...
Compatible test strips for blood glucose meters.
Drugs
Conditions
News and resources
